Clinical trials: Non ST-elevation Myocardial Infarction
Coronary Artery Disease, Unstable Angina
Restore EF Observational Study
A multi-center, prospective, observational, non-interventional single arm, study of the intermediate-term clinical outcomes collected from electronic health records of high-risk patients which have previously undergone standard…
- Conditions
- Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCT04648306
- Testing
- Prophylactic Impella support for a non-emergent PCI
- Where
- 21 sites in United States
- Volunteers
- 406 people
- Sponsor
- Abiomed Inc.
Acute Coronary Syndrome, Angina Pectoris
Diagnostic Performance of Artificial Intelligence Algorithms in Prediction of Acute Coronary Syndrome Based on White Blood Cell Properties
The goal of this observational study is to evaluate whether artificial intelligence (AI) algorithms can predict or exclude acute coronary syndrome (ACS) in adults using data generated by routine hematology testing.
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, NSTEMI - Non-ST Segment Elevation MI, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT06384846
- Where
- Austria
- Volunteers
- 3,350 people, healthy volunteers welcome
- Sponsor
- RobotDreams GmbH
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III All-comers Orsiro Safety and Performance Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-III (NCT01553526)
- Where
- 43 sites in Austria, Chile and 11 more
- Volunteers
- 1,356 people
- Sponsor
- Biotronik AG
Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI)
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.
- Conditions
- Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)
- Trial name
- NCT01020383
- Testing
- ALX-0081, ReoPro®
- Where
- 39 sites in Austria, Belgium and 5 more
- Volunteers
- 364 people
- Sponsor
- Ablynx, a Sanofi company
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel
Heart Attack, Cardiac Event
Mobile Advanced Multi-Parameter Reporting in Patients Wearing a Novel Device: Utilization During Cardiac Rehabilitation
Advanced remote multi-parameter reporting during cardiac rehabilitation (MAPS-III). The primary purpose of this observational study is to collect baseline information of cardiac rehabilitation usage in the US for post-myocardial…
- Conditions
- Heart Attack, Cardiac Event, Cardiac Disease, Cardiac Infarct
- Trial name
- MAPS-III (NCT05957172)
- Testing
- ZOLL Arrhythmia Management System
- Sponsor
- Zoll Medical Corporation
Coronary Artery Disease
Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease
This prospective, single-arm, multi-center, safety and feasibility first-in-human study will evaluate the safety and feasibility of the SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter to treat de-novo lesions between ≥2.0 and…
- Trial name
- ADVANCE-DCB (NCT05521542)
- Testing
- SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter
- Where
- 5 sites in Australia, Dominican Republic and 1 more
- Volunteers
- 28 people
- Sponsor
- Advanced NanoTherapies
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Angina, Unstable, Myocardial Infarction
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
- Trial name
- NCT00435487
- Testing
- Dalteparin ( Fragmin), Unfractionated heparin
- Where
- 8 sites in India
- Volunteers
- 173 people
- Sponsor
- Pfizer
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Sweden Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01667003
- Where
- 8 sites in Sweden
- Volunteers
- 406 people
- Sponsor
- Biotronik ApS
Angina Pectoris, Unstable Angina
Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization
The purpose of this study is to assess the safety and feasibility of a novel oxygen carrying solution, HBOC-201, in the setting of PCI for Acute Coronary Syndromes from randomization til hospital discharge.
- Conditions
- Angina Pectoris, Unstable Angina, Myocardial Infarction
- Trial name
- NCT00317512
- Testing
- Percutaneous Coronary Revascularization, Hemoglobin-Based Oxygen Carrier-201 (HBOC-201), Voluven
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 45 people
- Sponsor
- Biopure Corporation
Stable Angina, Unstable Angina
Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS
The purpose of the study is to demonstrate the non-inferiority of Cre8 (CID) Drug Eluting Stent, studied 3 months after implant, compared to Vision/Multilink8 Bare Metal Stent (Abbott) studied at 1 month, in terms of neointimal…
- Conditions
- Stable Angina, Unstable Angina, NSTEMI
- Trial name
- DEMONSTRATE (NCT01543373)
- Testing
- Amphilimus Eluting Stent, Bare Metal Stent
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 38 people
- Sponsor
- CID - Carbostent & Implantable Devices
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease, Coronary Syndrome
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With (N)STEMI or Unstable Angina
The POLARSTAR study is an early safety and feasibility study to evaluate the performance and safety of the CryoTherapy System (CTS) for the treatment of coronary plaque lesions that are not obstructing blood flow but are at…
- Conditions
- Coronary Artery Disease, Coronary Syndrome, Cryotherapy Effect, Myocardial Infarction
- Trial name
- POLARSTAR (NCT05600088)
- Testing
- CryoTherapy System (CTS)
- Where
- 5 sites in Georgia, Lithuania
- Volunteers
- 30 people
- Sponsor
- Cryotherapeutics SA
Acute Coronary Syndrome
VitalScan MCG Rule-out Multi-centre Pivotal Study - UK
The study is a prospective multi-centre observational study to evaluate a portable magnetocardiograph device for the rule-out of acute coronary syndrome (ACS) in patients who present to the emergency department with chest pain…
- Trial name
- MAGNET-ACS (NCT02921438)
- Testing
- VitalScan Magnetocardiograph
- Where
- 5 sites in United Kingdom
- Volunteers
- 756 people
- Sponsor
- Creavo Medical Technologies Ltd
Non-ST Elevation Myocardial Infarction (NSTEMI)
Prevention of Acute Kidney Injury in Patients With NSTEMI
A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with NSTEMI undergoing urgent coronary angiography.
- Trial name
- AKI (NCT04912141)
- Where
- 4 sites in Switzerland
- Volunteers
- 29 people
- Sponsor
- Pharming Technologies B.V.
Acute Coronary Syndrome
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission.
- Trial name
- ACS (NCT07102628)
- Testing
- Inclisiran
- Where
- 69 sites in Argentina, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
ACS - Acute Coronary Syndrome, NSTEMI - Non-ST Segment Elevation MI
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting.
- Trial name
- NCT06095557
- Testing
- Sponsor MCG device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- SB Technology, Inc.